Tianzhong Kangyuan Pharmaceutical has appointed Professor Mu Yuguang and his team from Nanyang Technological University as the chief research team

Tianzhong Kangyuan Pharmaceutical Group Reaches Important Milestone in Scientific R&D and Technological Innovation  In a significant advancement for scientific research and technological innovation, Tianzhong Kangyuan Pharmaceutical Group has officially signed an in-depth strategic cooperation agreement with a top-tier AI biomedical research team from the School of Life Sciences at Nanyang University of Singapore. The agreement was formalized under the leadership of renowned senior Professor Mu Yuguang.  Additionally, the Group has appointed Professor Mu Yuguang and five core Ph.D. members of his team as the Chief Scientific Research Team of Tianzhong Kangyuan Pharmaceutical Group. General Manager Cao Yu personally presented the letters of appointment. The signing ceremony was held at the Group's headquarters, with Sheng Qinyong, Vice Chairman of the Dongying Municipal Chinese People's Political Consultative Conference (CPPCC), and Ma Xianzhong, Vice Chairman of the Dongying District CPPCC, in attendance. Both leaders also participated in a specialized technical seminar on the collaboration.

The core of this collaboration lies in the deep integration of cutting-edge biotechnology and AI artificial intelligence, focusing on two key frontier directions: 

1. AI-Enabled Microbial Fermentation and Bio-active Extraction Technology By leveraging AI algorithms to deeply optimize microbial fermentation processes, the partnership aims to significantly enhance the yield, purity, stability, and targeted efficacy of bio-active compounds. AI will also be applied to improve strain selection and cultivation parameters, boosting the yield of active substances, quality, human absorption rates, and functional effectiveness. This will establish a highly efficient and controllable raw material foundation for future R&D. 

2. Functional Research and Innovative Product Development in Health & Wellness Utilizing AI-optimized high-activity fermentation ingredients and AI-driven human modeling, the two parties will focus on targeted health benefits, including immune system enhancement, liver function protection, metabolic fat reduction, inhibition of excessive melanin production, and reduction of dark spot formation. 

Sheng Qinyong, Vice Chairman of the Municipal CPPCC, highly praised the forward-looking and strategic significance of this university-enterprise collaboration. He emphasized that combining academia’s pioneering innovation capabilities with industry’s commercialization strengths—particularly in the critical field of AI-powered bio-manufacturing—fully aligns with the city’s strategic goal of building a globally competitive bio-pharmaceutical industry cluster. He expressed hope for early breakthroughs that would benefit public health.  

Professor Mu Yuguang Unveils Collaborative Vision at Seminar： During the symposium, Professor Mu Yuguang elaborated on the partnership’s vision: "AI’s 'precision cultivation' in the microbial world will unlock the full potential of bio-synthetic processes, overcoming bottlenecks in traditional methods. By joining forces with industry, we aim to bridge the 'last mile' from laboratory discovery to scaled production—ensuring cutting-edge scientific achievements are swiftly and effectively translated into tangible health solutions for the public, particularly in the realm of medicinal-food homologous bio-formulations.

During the seminar, the two sides also reached consensus on innovative cooperation mechanisms such as "intellectual property equity participation" and "clinical institutions participating in efficacy verification", promoting the leap of laboratory technology to "production of therapeutic grade raw materials and development of therapeutic products".

Cao Yu, general manager of the group, said that this strong alliance is a key move in the company's AI+ biotechnology strategy. It will rely on the strong scientific research strength of Professor Mu Yuguang's team from the School of Life Sciences, Nanyang Technological University to accelerate the upgrade and iteration of its own technology platform and jointly develop a new generation of health products with global market competitiveness.The group plans to invest 50 million yuan in the first phase to establish a joint laboratory and develop AI models. It is expected that at least one core technology will be industrialized within two years. AI + biotechnology offers an innovative approach for the group to tackle key challenges in the health sector. The outcomes of this collaboration are expected to significantly impact the market for various biological raw materials, traditional Chinese medicine, health foods, functional foods, and nutritional supplements of the group in the future. This partnership marks a significant step forward in the group's efforts to develop new productive forces and promote collaborative innovation among industry, academia, and research.